700
Participants
Start Date
July 31, 2011
Primary Completion Date
September 30, 2027
Study Completion Date
September 30, 2027
Leuprorelin Acetate
Leuprorelin Acetate 45 mg, one injection every 6 months for 24 months
Institut Paoli Calmettes, Marseille
Hopital Nord, Marseille
Chu Bocage, Dijon
Centre Hopsitalier Prive - Polyclinique Du Littoral, Saint-Brieuc
Chu Besancon, Besançon
Chru de Brest, Brest
Chu Caremeau, Nîmes
Chu Rangueil, Toulouse
Chu Bordeaux- Hopital Pellegrin, Bordeaux
Institut Bergonie, Bordeaux
Clinique Beausoleil, Montpellier
Hopital Lapeyronie, Montpellier
Chu Pontchaillou, Rennes
Clinique Mutualiste, Saint-Etienne
Chu Nantes, Nantes
Institut Jean Godinot, Reims
Chu de Nancy, Nancy
Chru Lille, Lille
Chu Strasbourg, Strasbourg
Hopitaux Civils de Colmar, Strasbourg
Hopital Edouard Herriot, Lyon
Hopital Saint Louis, Paris
Hopital Cochin, Paris
Institut Mutualiste Montsouris, Paris
HEGP, Paris
Hopital Tenon, Paris
Hopital Pitie Salpetriere, Paris
Hopital Charles Nicolle, Rouen
Clinique Victor Pauchet, Amiens
Centre Hospitalier Departemental, La Roche-sur-Yon
Chu La Miletrie, Poitiers
Chu Limoges, Limoges
Hopital Foch, Suresnes
Hopital Henri Mondor, Créteil
Chu Pasteur, Nice
Collaborators (1)
Astellas Pharma Inc
INDUSTRY
UNICANCER
OTHER